Entrada Therapeutics Q2 2024 GAAP EPS $1.55 May Not Be Comparable To $0.10 Estimate, Sales $94.694M May Not Be Comparable To $46.075M Estimate
Portfolio Pulse from Benzinga Newsdesk
Entrada Therapeutics reported Q2 2024 GAAP EPS of $1.55, which may not be comparable to the $0.10 estimate. Sales were $94.694M, which may not be comparable to the $46.075M estimate.
August 13, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entrada Therapeutics reported Q2 2024 GAAP EPS of $1.55, which may not be comparable to the $0.10 estimate. Sales were $94.694M, which may not be comparable to the $46.075M estimate.
The significant difference between reported and estimated EPS and sales figures suggests a strong performance by Entrada Therapeutics. This is likely to positively impact the stock price in the short term as investors react to the better-than-expected results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100